Immatics Appoints Cedrik Britten as Chief Medical Officer
Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical company active in the discovery and development of T c…
Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical company active in the discovery and development of T c…
Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical Company active in the discovery and development of T-c…
Clinical study demonstrates proof-of-concept for active personalized immunotherapy approach in a pioneering multi-center…
The prospect of an actively personalized approach to the treatment of glioblastoma has moved a step closer with the rece…
Amgen (NASDAQ:AMGN) and Immatics Biotechnologies GmbH, a leading company in the field of cancer immunotherapy, today…
. - Regulatory authority approves clinical trial for Glioma Actively Personalized Vaccine Consortium (GAPVAC) - First…
immatics biotechnologies GmbH und Roche (SIX: RO, ROG; OTCQX: RHHBY) haben heute bekannt gegeben, dass sie ein strategis…
immatics biotechnologies GmbH and Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced a strategic research and developmen…
. - Glioma Actively Personalized Vaccine Consortium (GAPVAC): 14 organizations in Europe and the US join forces to deve…
immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that…